These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 10190653)

  • 21. Effects of imidapril on left ventricular mass in chronic hemodialysis patients.
    Matsumoto N; Ishimitsu T; Okamura A; Seta H; Takahashi M; Matsuoka H
    Hypertens Res; 2006 Apr; 29(4):253-60. PubMed ID: 16778332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduction (TELMAR) as assessed by magnetic resonance imaging in patients with mild-to-moderate hypertension--a prospective, randomised, double-blind comparison of telmisartan with metoprolol over a period of six months rationale and study design.
    Friedrich MG; Dahlöf B; Sechtem U; Unger T; Knecht M; Dietz R;
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):234-43. PubMed ID: 14689371
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Left ventricular systolic function after marked reduction of ventricular hypertrophy induced by 5 years' enalapril treatment.
    González-Juanatey JR; Pose Reino A; García Acuña JM; Castelo Fuentes V; Amaro Gendón A; Calvo Gómez C; Gil de la Peña M
    Eur Heart J; 1995 Dec; 16(12):1981-7. PubMed ID: 8682036
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fosinopril. Clinical pharmacokinetics and clinical potential.
    Shionoiri H; Naruse M; Minamisawa K; Ueda S; Himeno H; Hiroto S; Takasaki I
    Clin Pharmacokinet; 1997 Jun; 32(6):460-80. PubMed ID: 9195116
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of losartan and atenolol on left ventricular mass and neurohormonal profile in patients with essential hypertension and left ventricular hypertrophy.
    Dahlof B; Zanchetti A; Diez J; Nicholls MG; Yu CM; Barrios V; Aurup P; Smith RD; Johansson M;
    J Hypertens; 2002 Sep; 20(9):1855-64. PubMed ID: 12195129
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiorenal protective effects of vasopeptidase inhibition with omapatrilat in hypertensive transgenic (mREN-2)27 rats.
    Mifsud SA; Burrell LM; Kubota E; Jaworski K; Cooper ME; Wilkinson-Berka JL
    Clin Exp Hypertens; 2004 Jan; 26(1):69-80. PubMed ID: 15000298
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A; Suzuki Y; Saruta T
    Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of nitrendipine and enalapril on left ventricular mass in patients with non-insulin-dependent diabetes mellitus and hypertension.
    Gerritsen TA; Bak AA; Stolk RP; Jonker JJ; Grobbee DE
    J Hypertens; 1998 May; 16(5):689-96. PubMed ID: 9797181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regression of left ventricular hypertrophy in human hypertension with irbesartan.
    Malmqvist K; Kahan T; Edner M; Held C; Hägg A; Lind L; Müller-Brunotte R; Nyström F; Ohman KP; Osbakken MD; Ostergern J
    J Hypertens; 2001 Jun; 19(6):1167-76. PubMed ID: 11403367
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diverse effects of chronic treatment with losartan, fosinopril, and amlodipine on apoptosis, angiotensin II in the left ventricle of hypertensive rats.
    Yu G; Liang X; Xie X; Su M; Zhao S
    Int J Cardiol; 2001 Dec; 81(2-3):123-9; discussion 129-30. PubMed ID: 11744126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Value of rilmenidine therapy and its combination with perindopril on blood pressure and left ventricular hypertrophy in patients with essential hypertension (VERITAS).
    Farsang C; Lengyel M; Borbás S; Zorándi A; Dienes BS;
    Curr Med Res Opin; 2003; 19(3):205-17. PubMed ID: 12803735
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regression of left ventricular hypertrophy in hypertensive patients after 1 year of treatment with rilmenidine: a double-blind, randomized, controlled (versus nifedipine) study.
    Sadowski Z; Szwed H; Kuch-Wocial A; Kubasik A; Januszewicz W; Krupa-Wojciechowska B; Polak G; Stejfa M; Dvorak I; Balazovjech I; Dubai G; Simon K
    J Hypertens Suppl; 1998 Aug; 16(3):S55-62. PubMed ID: 9747912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Both a calcium antagonist and ACE inhibitor reverse hypertrophy in hypertension but a calcium antagonist also depresses contractility.
    Sumimoto T; Ochi T; Ito T; Joh T; Muneta S; Hiwada K
    Cardiovasc Drugs Ther; 1997 Mar; 11(1):27-32. PubMed ID: 9140674
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Left ventricular (LV) geometry and dipping state are determinants of LV mass reduction with angiotensin-converting enzyme inhibitor antihypertensive treatment.
    Aznaouridis KA; Vyssoulis GP; Karpanou EA; Marinakis AG; Barbetseas JD; Zervoudaki AI; Cokkinos DV; Stefanadis CI
    Blood Press Monit; 2007 Apr; 12(2):87-94. PubMed ID: 17353651
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of once-daily angiotensin-converting enzyme inhibition and calcium channel blockade-based antihypertensive treatment regimens on left ventricular hypertrophy and diastolic filling in hypertension: the prospective randomized enalapril study evaluating regression of ventricular enlargement (preserve) trial.
    Devereux RB; Palmieri V; Sharpe N; De Quattro V; Bella JN; de Simone G; Walker JF; Hahn RT; Dahlöf B
    Circulation; 2001 Sep; 104(11):1248-54. PubMed ID: 11551875
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of fosinopril on cardiac and metabolic parameters in patients with NIDDM.
    Holdaway IM; Gamble GD; Sanders GA; Greaves SC; Ellis-Pegler EM; Sharpe N
    Diabetes Care; 1994 Dec; 17(12):1476-9. PubMed ID: 7882821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of fosinopril on cardiac function in patients with hypertension. Radionuclide assessment of left ventricular systolic and diastolic performance.
    Zusman RM; Christensen DM; Higgins J; Boucher CA
    Am J Hypertens; 1992 Apr; 5(4 Pt 1):219-23. PubMed ID: 1534664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors.
    Kohno M; Yokokawa K; Minami M; Kano H; Yasunari K; Hanehira T; Yoshikawa J
    Am J Med; 1999 May; 106(5):544-9. PubMed ID: 10335726
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism.
    Stavroulakis GA; Makris TK; Krespi PG; Hatzizacharias AN; Gialeraki AE; Anastasiadis G; Triposkiadis P; Kyriakidis M
    Cardiovasc Drugs Ther; 2000 Aug; 14(4):427-32. PubMed ID: 10999650
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of antihypertensive effects of once-a-day isradipine and fosinopril: a double-blind crossover study by means of ambulatory blood pressure monitoring.
    Perticone F; Pugliese F; Marcantonio AM; Cloro C; Maio R; Mattioli PL
    Clin Cardiol; 1995 Jul; 18(7):401-7. PubMed ID: 7554545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.